Sign in →

Test ID CLFA Cryptococcus Antigen Screen with Titer, Spinal Fluid


Specimen Required


Container/Tube: Sterile vial

Specimen Volume: 1 mL


Forms

If not ordering electronically, complete, print, and send Infectious Disease Serology Test Request (T916) with the specimen.

Secondary ID

62074

Useful For

Aiding in the diagnosis of cryptococcosis

 

This test should not be performed as a screening procedure for the general population.

 

This test should not be used as a test of cure or to guide treatment decisions.

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
CLFAT Cryptococcus Ag Titer, LFA, CSF Yes No

Testing Algorithm

If result is positive, Cryptococcus titer will be performed at an additional charge.

 

For more information see Meningitis/Encephalitis Panel Algorithm

Method Name

Lateral Flow Assay (LFA)

Reporting Name

Cryptococcus Ag Screen w/Titer, CSF

Specimen Type

CSF

Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time
CSF Refrigerated (preferred) 14 days
  Frozen  14 days

Clinical Information

Cryptococcosis is an invasive fungal infection caused by Cryptococcus neoformans or Cryptococcus gattii. C neoformans has been isolated from several sites in nature, particularly weathered pigeon droppings. C gattii was previously only associated with tropical and subtropical regions. More recently, however, this organism has been found to be endemic in British Columbia and the Pacific Northwestern United States and is associated with several different tree species.

 

Infection is usually acquired via the pulmonary route. Patients are often unaware of any exposure history. Approximately half of the patients with symptomatic disease have a predisposing immunosuppressive condition such as AIDS, steroid therapy, lymphoma, or sarcoidosis. Symptoms may include fever, headache, dizziness, ataxia, somnolence, and cough. While the majority of C neoformans infections occur in immunocompromised patient populations, C gattii has a higher predilection for infection of healthy individuals.(1,2)

 

In addition to the lungs, cryptococcal infections frequently involve the central nervous system (CNS), particularly in patients infected with HIV. Mortality among patients with CNS cryptococcosis may approach 25% despite antibiotic therapy. Untreated CNS cryptococcosis is invariably fatal. Disseminated disease may affect any organ system and usually occurs in immunosuppressed individuals.

Reference Values

Negative

Reference values apply to all ages.

Cautions

A traumatic lumbar puncture and contamination of the cerebrospinal fluid (CSF) specimen with plasma may lead to a positive Cryptococcus antigen result from CSF in patients without neuroinvasive cryptococcosis.

 

A negative result does not preclude diagnosis of cryptococcosis, particularly if only a single specimen has been tested and the patient shows symptoms consistent with cryptococcosis.

 

A positive result is indicative of cryptococcosis; however, all test results should be reviewed in light of other clinical findings.

 

Testing should not be performed as a screening procedure for the general populations and should only be performed when clinical evidence suggests the diagnosis of cryptococcal disease.

 

Although rare, extremely high concentrations of cryptococcal antigen can result in weak test lines and in extreme instances, yield false-negative test results.

 

This assay has not been evaluated for cross-reactivity in patients with trichosporonosis.

Day(s) Performed

Monday through Sunday

Report Available

Same day/1 to 2 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

87899-Cryptococcus screen

87899-Cryptococcus titer (if appropriate)

NY State Approved

Yes